Kaletra Monotherapy in HIV/HCV Co-infected Subjects

Inclusion Criteria

1. Subject has confirmed his or her willingness to participate in the study after being informed of all aspects of the trial that are relevant to his or her decision to participate, by signing and dating the IRB / IEC approved informed consent form.
2. Subject is both HIV positive and HCV positive (must be viremic for HCV, not just antibody positive).
3. Subject is 18 years of age or older.
4. Subject must have an undetectable viral load (VL) less than 50 copies/ml for the last 6 months on HAART therapy.
5. Subject must not be taking any medication that could interact with Kaletra® to enhance hepatic toxicity.
6. Subject's serum AST and ALT levels must be <5 times normal (grade 2 or less) at the start of the study.
7. Subject must not harbour viral strains that are resistant to Kaletra® at the start of the study.
8. Subject has a Karnofsky Score 70 or greater.
9. If female, subject must have a negative pregnancy test and agree to use, for the duration of the study, a barrier method of birth control that has a history of proven reliability as judged by the investigator.
10. Subject does not require and agrees not to take, for the duration of the study, any medication that is contraindicated with Kaletra® (list will be in the protocol).

Exclusion Criteria

1. Subject has active hepatitis B (HbsAg +).
2. Subject has a history of substance abuse or psychiatric illness that could preclude compliance with the protocol.

3. Subject has any of the following abnormal laboratory test results at screening:

   • Hemoglobin 8.0 g/dL or more
   • Absolute neutrophil count 500 cells/mL or more
   • Platelet count 20,000/mL or more
   • ALT or AST 5x Upper Limit of Normal (ULN) or more
   • Creatinine 1.5 x ULN or more
4. Female subject is pregnant or lactating.
5. Subject has received an investigational drug within 30 days prior to the initiation of study dosing.
6. Subject exhibits viral strains that are resistant to lopinavir.
7. Subject is receiving systemic chemotherapy.
8. The subject, in the opinion of the principal investigator, is unlikely to comply with the study protocol or is unsuitable for any other reason.